benmelstobart

Home
Ligands
benmelstobart

GtoPdb Ligand ID: 13790

Synonyms: Andervi® | APL 502 | APL502 | TQB-2450 | TQB2450

benmelstobart is an approved drug

Comment: Benmelstobart (TQB2450) is a fully humanised anti-programmed cell death 1 ligand 1 (PD-L1) monoclonal antibody. It was developed to treat advanced solid tumours by blocking the inhibitory the PD-1/PD-L1/L2 immune checkpoint.

References
1. Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N, Huang C, Wei S, Sun H, Li X et al.. (2024) Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat Med, 30 (10): 2967-2976. [PMID:38992123]
2. Lan CY, Zhao J, Yang F, Xiong Y, Li R, Huang Y, Wang J, Liu C, Bi XH, Jin HH et al.. (2022) Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial. Cell Rep Med, 3 (7): 100689. [PMID:35858589]
3. Ning T, Li D, Deng T, Bai Y, Chen Y, Wang Z, Hu B, Ba Y, Lu W. (2024) Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study. Cancer, 130 (18): 3137-3146. [PMID:38781433]
4. Tan Z, Wu Y, Fan Z, Gao T, Guo W, Bai C, Xue R, Li S, Zhang L, Wang X et al.. (2024) Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial. Clin Cancer Res, 30 (24): 5577-5583. [PMID:39453774]
5. Zhang W, Wang J, Wang Q, Cheng Y, Yang L, Li Y, Zhong H, Chu T, Dong Y, Zhang Y et al.. (2023) A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer. Lung Cancer, 184: 107353. [PMID:37647728]
6. Zhou J, Sun Y, Zhang W, Yuan J, Peng Z, Wang W, Gong J, Yang L, Cao Y, Zhao H et al.. (2023) Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Hepatology, 77 (1): 65-76. [PMID:35491432]

References

1. Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N, Huang C, Wei S, Sun H, Li X et al.. (2024)
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.
Nat Med, 30 (10): 2967-2976. [PMID:38992123]

2. Lan CY, Zhao J, Yang F, Xiong Y, Li R, Huang Y, Wang J, Liu C, Bi XH, Jin HH et al.. (2022)
Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial.
Cell Rep Med, 3 (7): 100689. [PMID:35858589]

3. Ning T, Li D, Deng T, Bai Y, Chen Y, Wang Z, Hu B, Ba Y, Lu W. (2024)
Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
Cancer, 130 (18): 3137-3146. [PMID:38781433]

4. Tan Z, Wu Y, Fan Z, Gao T, Guo W, Bai C, Xue R, Li S, Zhang L, Wang X et al.. (2024)
Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial.
Clin Cancer Res, 30 (24): 5577-5583. [PMID:39453774]

5. Zhang W, Wang J, Wang Q, Cheng Y, Yang L, Li Y, Zhong H, Chu T, Dong Y, Zhang Y et al.. (2023)
A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer.
Lung Cancer, 184: 107353. [PMID:37647728]

6. Zhou J, Sun Y, Zhang W, Yuan J, Peng Z, Wang W, Gong J, Yang L, Cao Y, Zhao H et al.. (2023)
Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
Hepatology, 77 (1): 65-76. [PMID:35491432]